Pervaiz Iqbal, MD
Pulmonary Disease · South Richmond Hill, NYNPI 1083658918
Payments from drug & device makers
Across 226 payments — averaging $26.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Philips North America LLC$364
- Abbott$304
- Phathom Pharmaceuticals, Inc.$208
- Lilly USA, LLC$207
- plus $1K from 20 others
What the payments were for
- Food & beverage$5,77198%
- Education$1132%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 115 | $2,364 |
| GSK | 52 | $1,323 |
| Philips North America LLC | 5 | $364 |
| Abbott | 3 | $304 |
| Phathom Pharmaceuticals, Inc. | 9 | $208 |
| Lilly USA, LLC | 11 | $207 |
| Olympus America Inc. | 1 | $144 |
| Lexicon Pharmaceuticals, Inc. | 1 | $125 |
| Amgen | 1 | $125 |
| Baxter Healthcare | 4 | $98 |
| Actelion Pharmaceuticals US, Inc. | 1 | $90 |
| Exact Sciences | 3 | $80 |
| Boehringer Ingelheim | 3 | $72 |
| Bayer | 2 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $54 |
| Sanofi | 2 | $54 |
| Insmed, Inc. | 2 | $45 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Novo Nordisk | 1 | $23 |
| Shield Therapeutics Inc | 1 | $22 |
| Circassia Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$250
- SPiN Vision Video Processor$144
- Inpefa$125
- BREZTRI$125
- Repatha$125
- IGT D Coronary$107
How this compares
$5,884 in reported general payments places this provider in the 70th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 243 | $187,968 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 225 | $162,164 |
| JardianceEmpagliflozin | 133 | $122,746 |
| OzempicSemaglutide | 105 | $112,422 |
| JanuviaSitagliptin Phosphate | 87 | $97,120 |
| JanumetSitagliptin Phos/Metformin Hcl | 99 | $78,249 |
| MounjaroTirzepatide | 59 | $68,669 |
| Fasenra PenBenralizumab | 11 | $63,091 |
| Breo ElliptaFluticasone/Vilanterol | 139 | $57,371 |
| TrulicityDulaglutide | 30 | $29,118 |
| Diclofenac Sodium | 74 | $28,721 |
| FarxigaDapagliflozin Propanediol | 41 | $25,357 |
| EliquisApixaban | 31 | $22,666 |
| RybelsusSemaglutide | 21 | $21,422 |
| SymbicortBudesonide/Formoterol Fumarate | 67 | $17,395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,323 | $271,114434 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Airsupra | $2,364 | $212,663344 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Combivent Respimat | $72 | $149,554178 claims |
| Novo NordiskOzempic, Rybelsus | $23 | $133,844126 claims |
| Lilly USA, LLCMounjaro, Trulicity | $207 | $97,78789 claims |
| Johnson & JohnsonXarelto | $14 | $9,13711 claims |
| BayerKerendia | $57 | $7,36912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in South Richmond Hill
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.